ESC 365 - Doctor Vincenzo Quagliariello

Speaker illustration

Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

Dr. Quagliariello Vincenzo has achieved an International PhD in Translational Medicine in 2015, studying the biochemistry and pathophysiology of cancer, with particular attention to the nanomedicine as a new tool for cancer diagnosis and therapy. From 2016 he studies the pathological characteristics of the cardiotoxicity induced by anticancer drugs, with particular reference to cardioprotection strategies through drugs or new formulations (nanotechnologies). Dr. Quagliariello specifically analyzes the inflammosome and cardiac/vascular microenvironment and their role in cardiotoxicity phenomena. Other professional interests of Dr. Quagliariello are related to nutraceuticals, endocrine disruptors exposure and the study of the main cardiovascular risk factors in cancer patients.

Dapagliflozin prevents ejection fraction and fractional shortening reduction, reduces myocardial NF-KB expression and systemic pro-inflammatory biomarkers in models of doxorubicin cardiotoxicity

Event: EuroEcho-Imaging 2024

Topic: Myocardial Disease

Session: Poster session 1

Fructose exacerbates anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: new roles of sweeteners in cardio-oncology

Event: Heart Failure 2024

Topic: Cardio-Oncology

Session: Cardiovascular disease in special populations - cardio-oncology (1)

Combinatorial immune checkpoint blockade increases myocardial secretion of H-FABP, NT-Pro-BNP, NLRP-3, IL-1 and IL6: clinical implications in cardio-immuno-oncology

Event: Heart Failure 2024

Topic: Cardio-Oncology

Session: Young Investigator Award (YIA) Basic Science

Ipilimumab, pembrolizumab and nivolumab exerts different cardiac and vascular toxicity through DAMPs fibronectin-EDA, S100/calgranulin, galectine-3 and associated NLRP3 inflammasome-chemokine pathway

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Dapagliflozin enhanced the anticancer effects of the CTLA-4 blocking agent ipilimumab reducing its cardiotoxicity through galectine-3, Trimethylamine N-oxide (TMAO) and NLRP-3

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Fructosilation products and low doses of advanced glycation end-products promotes premature cell death of cardiac cells exposed to doxorubicin via activation of NLRP3, MyD88 and p53 downregulation

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Dapagliflozin associated to sacubitril/valsartan exerts additive cardioprotection during exposure to doxorubicin and trastuzumab through improvement of mytogenesis and reduction of MyD88/NLRP3

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Palmitoylethanolamide (PEA) reduces inflammation in cardiomyocytes and endothelial cells exposed to doxorubicin and trastuzumab through PPAR-a and NLRP3

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Sacubitril/valsartan improves ejection fraction and longitudinal strain in mice exposed to doxorubicin through the reduction of trimethylamine N-oxide, NLRP3 inflammasome and Galectine-3

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Co-incubation of evolocumab with trastuzumab emtansine (T-DM1) reduces cardiotoxicity through the reduction of MyD88-NLRP3 and galectine-3

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources